Clinical Trials Logo

Left Ventricular Dysfunction clinical trials

View clinical trials related to Left Ventricular Dysfunction.

Filter by:

NCT ID: NCT06387862 Recruiting - Clinical trials for Left Ventricular Dysfunction

Pharmacokinetics of Inhaled Levosimendan

Symbiov
Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

Determination of biological availability, time-to-peak and elimination half-life of inhaled levosimendan by administration of an inhaled- and intravenous dose of levosimendan.

NCT ID: NCT06356727 Recruiting - Heart Failure Clinical Trials

Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling

MICROREV
Start date: January 3, 2024
Phase: N/A
Study type: Interventional

Patients presenting with idiopathic dilated cardiomyopathy and left ventricle dysfunction (LVEF <40%), naive of anti-remodeling cardiac medical therapy, will undergo invasive coronary microvascular assessment based on thermodilution. The primary endpoint, namely the left ventricle reverse remodeling, will be assessed after 12 months of optimal medical therapy based on transthoracic echocardiography. The primary endpoint will be evaluated by an independent central core lab. Patients enrolled in the study will be followed for a period of 5 years to monitor their clinical status. During the study period participants may undergo multimodality diagnostic tests including ECG telemetry monitoring, cardiopulmonary exercise testing, cardiovascular cardiac magnetic resonance.

NCT ID: NCT06197256 Completed - COVID-19 Clinical Trials

Cardiac Dysfunction in Critically Ill Covid-19 Patients

Start date: May 7, 2020
Phase:
Study type: Observational

We conducted an observation sub-study of the prospective randomized controlled trial "High Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure", in which we analysed the echocardiographic data collected both at baseline when patients where included and 3-5 days later for followup.

NCT ID: NCT06088212 Not yet recruiting - Heart Failure Clinical Trials

Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor

Cog-HF
Start date: December 2023
Phase: N/A
Study type: Interventional

This study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure. This program aims to improve cognition, reduce dementia risk and cardiovascular events, and will be supported by innovative digital technology for wide scale rollout and implementation. Findings from this research will transform the way healthcare is delivered to cognitively impaired patients with heart disease who have a very high risk of developing dementia.

NCT ID: NCT06084468 Active, not recruiting - Stroke Clinical Trials

Cardiac Structure and Function in Patients With Cystic Fibrosis

Start date: January 1, 2023
Phase:
Study type: Observational

In a prospective observational cohort study (n = 100), the investigators aim to assess the correlation between cardiac biomarkers, advanced echocardiography and cystic fibrosis genotype and severity and determine whether these are prognostic markers of heart disease in patients suffering from cystic fibrosis (CF).

NCT ID: NCT05989945 Recruiting - Stroke Clinical Trials

HIDRAdenitis Suppurativa and HEART Disease

Start date: August 1, 2023
Phase:
Study type: Observational

In a prospective observational cohort study (n = 250) the investigators aim to assess the correlation between cardiac biomarkers, advanced echocardiography and HS severity and determine whether these are prognostic markers of heart disease in patients suffering from hidradenitis suppurativa (HS).

NCT ID: NCT05939089 Completed - Heart Failure Clinical Trials

Cardiovascular Assessment of Pediatric Cancer Survivors

CASPER
Start date: January 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to evaluate cardiac and vascular health status of pediatric cancer survivors.

NCT ID: NCT05860504 Recruiting - Clinical trials for Myocardial Infarction

Acute Cardiac Dysfunction in Critical Illnes

Start date: May 29, 2023
Phase:
Study type: Observational

The overall aim of the study is to establish the clinical importance of cardiac dysfunction, by estimating its incidence and impact on short- and long-term outcomes, in a mixed population of critically ill patients with multi-organ failure. Pathogenesis of cardiac dysfunction in critical illness and key molecules linked to this will be explored.

NCT ID: NCT05769036 Recruiting - Heart Failure Clinical Trials

Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients

RECOVER-HF
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

Heart failure (HF) is the most common nosology encountered in clinical practice. Its incidence and prevalence increase exponentially with increasing age and it is associated with increased mortality, more frequent hospitalization and decreased quality of life. An initial approach to the treatment of HF patients with reduced left ventricular (LV) systolic function and left bundle branch block (LBBB) was implantation of cardioresynchronization device using biventricular pacing. This has resulted in long-term clinical benefits such as improved quality of life, increased functional capacity, reduced HF hospitalizations and overall mortality. However, conventional cardiac resynchronization therapy (CRT) is effective in only 70% of patients. And the remaining 30% of patients are non-responders to conventional CRT. Subsequently, His bundle pacing (HBP) has been developed to achieve the same results. According to other studies HBP has showed greater improvement in hemodynamic parameters than with conventional biventricular CRT. But, nevertheless, there are significant clinical troubles with HBP. In this regard, in 2017, the left bundle branch pacing (LBBP) was developed, which demonstrated clinical advantages compared to biventricular CRT. This method has become an alternative to HBP due to the stimulation of LBB outside the blocking site, a stable pacing threshold and a narrow QRS duration. A series of case reports and observational studies have demonstrated the efficacy and safety of LBBP in patients with CRT indications. However, it is not enough data about CRT with LBBP effectiveness in LV remodeling, reducing mortality and complications. According to our hypothesis, CRT with LBBP compared with conventional biventricular CRT will significantly improve the clinical outcomes and reverse LV remodeling in patients with chronic HF with reduced LV ejection fraction and reduce the number of non-responders to conventional CRT.

NCT ID: NCT05764057 Recruiting - STEMI Clinical Trials

DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

DAPAPROTECTOR
Start date: June 12, 2023
Phase: Phase 3
Study type: Interventional

Recent clinical trials have proven the cardiovascular benefits of new medications for patients with heart failure with reduced ejection fraction (HFrEF), especially sodium-glucose co-transporter 2 (SGLT2) inhibitors. There are no existing randomized clinical trials evaluating the efficacy and safety of dapagliflozin (nor any other SGLT2-inhibitor) to limit cardiac remodeling in patients with acute myocardial infarction (AMI) and left ventricular (LV) dysfunction. Preventing cardiac remodeling, an established predictor of subsequent heart failure (HF) and cardiovascular death, is likely to translate into benefit in reducing clinical events in post-MI patients.